Methods for Administering Active Agents to CYP3A4 Sensitive Patients
The present invention relates, in part, to the discovery that parenterally administered extended release formulations possess an unexpected advantage in treating patients possessing active CYP 3A4. This advantage is particularly beneficial where the individual is concomitantly administering a CYP 3A4 inhibitor or is in risk of doing so. Thus, the invention relates to a method for treating individuals possessing a functional CYP3A4 gene with an active agent metabolized by CYP3A4 comprising parenterally administering the active agent in a first extended release formulation in a first administration and the formulations for use in such methods. The invention further includes a method for preventing adverse drug reactions in individuals possessing a functional CYP3A4 gene with an active agent metabolized by CYP3A4 comprising parenterally administering the active agent in a first extended release formulation in a first administration.
1 . A method for treating individuals, wherein the individuals (a) possess a functional CYP3A4 gene, (b) are being administered a CYP3A4 inhibitor and (c) are in need of an extended administration of an active agent metabolized by CYP3A4 comprising parenterally administering the active agent in an extended release formulation wherein the extended release formulation releases the active agent over a period of at least about 7 days.
2 . The method of claim 1 wherein the CYP3A inhibitor is selected from the group consisting of fluconazole, omeprazole, saquinavir, quinine, ritonavir, nelfinavir, norfloxacine, sertraline, troleandomycin, diltiazem, delaviridine, nefazodone, zafirlukast, gestodene, amiodarone, cannabinoids, cimetidine, ciprofloxacin, clarithromycin, diethyldithiocarbamate, fluvoxamine, fluoxetine, mifepristone, grapefruit juice, indinavir, itraconazole, ketoconazole, metronidazole, mibefradil, miconazole, and erythromycin.
3 . The method of claim 2 wherein the individual is in need of treatment of a CNS disorder.
4 . The method of claim 3 wherein the individual is under psychiatric treatment.
5 . The method of claim 4 wherein the active agent is selected from the group consisting of antipsychotics, antidepressants, serotonin reuptake inhibitors, neuroleptics, and opioids.
6 . The method of claim 1 wherein the active agent is selected from the group consisting of aripiprazole, clozapine, rifampin, progesterone, propranolol, trazodone, prednisone, quinine, nitrendipine, ritonavar, R-warfarin, quinidine, taxol, ondansetron, nisoldipine, nimodipine, nifedipine, nicardipine, salmeterol, nelfinavir, triazolam, paclitaxel, verapamil, zolpidem, zaleplon, pravastatin, pimozide, haloperidol, caffeine, zileuton, terfenadine, vinblastine, saquinavir, methadone, testosterone, nefazodone, temazepam, tamoxifen, tacrolimus, simvastatin, sildenafil, sertraline, vincristine, chlorpheniramine, micronazole, dexamethasone, dapsone, cyclosporine, cyclophosphamide, cyclobenzaprine, codeine-N-demethylation, cocaine, clonazepam, clomipramine, clindamycin, diazepam, cisapride, diltiazem, cerivastatin, carbamazepine, cannabinoids, busulfan, buspirone, atorvastatin, astemizole, amlodipine, amitriptyline, alprazolalm, alfentanil, clarithromycin, frazodone, midazolam, mibefradil, lovastatin, losartan, lidocaine, lercadipine, lansoprazole, ketoconazole, isradipine, indinavir, imipramine, dextromethorphan, hydrocortisone, navelbine, finasteride, fexofenadine, fentanyl, felodipine, etoposide, ethosuximide, estrogens, estradiol, erythromycin, dronabinol, doxorubicin, donepezil, disopyramide, ifosfamide, and analogs thereof
7 . The method of claim 6 wherein the active agent is aripiprazole.
8 . The method of claim 1 wherein the active agent is administered intramuscularly or subcutaneously.
9 . The method of claim 1 further comprising a second administration of an active agent in a second extended release formulation at least about 7 days after the first administration.
10 . The method of claim 1 wherein the extended release formulation comprises a biodegradable polymer and the active agent.
11 . The method of claim 10 wherein the extended release formulation comprises a polylactide-co-glycolide and the active agent.
12 . The method of claim 11 wherein the active agent is aripiprazole.
13 . A method for treating individuals, wherein the individuals
(a) possess a functional CYP3A4 gene,
(b) are being administered a CYP3A4 inhibitor selected from the group consisting of fluconazole, omeprazole, saquinavir, quinine, ritonavir, nelfinavir, norfloxacine, sertraline, troleandomycin, diltiazem, delaviridine, nefazodone, zafirlukast, gestodene, amiodarone, cannabinoids, cimetidine, ciprofloxacin, clarithromycin, diethyldithiocarbamate, fluvoxamine, fluoxetine, mifepristone, indinavir, itraconazole, ketoconazole, metronidazole, mibefradil, miconazole, and erythromycin, and
(c) are in need of an extended administration of aripiprazole comprising parenterally administering aripiprazole in an extended release formulation wherein the extended release formulation releases the active agent over a period of at least about 7 days.